Rankings
▼
Calendar
CHRS Q1 2025 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena
CHRS
Coherus Oncology, Inc.
$226M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
+229.2% YoY
Gross Profit
$5M
65.1% margin
Operating Income
-$45M
-597.9% margin
Net Income
-$57M
-744.4% margin
EPS (Diluted)
$-0.49
QoQ Revenue Growth
-86.0%
Cash Flow
Operating Cash Flow
-$26M
Free Cash Flow
-$26M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$371M
Total Liabilities
$555M
Stockholders' Equity
-$183M
Cash & Equivalents
$82M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$2M
+229.2%
Gross Profit
$5M
$869,000
+469.2%
Operating Income
-$45M
-$68M
+33.0%
Net Income
-$57M
$103M
-155.0%
Revenue Segments
Product and Service, Other
$251,000
100%
← Q4 2024
All Quarters
Q2 2025 →